Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In The News: Tracking The Latest Industry Personnel Moves

Executive Summary

New top leadership at Critical Path Institute, NeurogesX; Former CMS Acting Administrator Frizzera joins FaegreBD Consulting. More personnel moves in this month’s column.

You may also be interested in...



A New Chapter, A New CEO For Dendreon

Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.

GPhA’s New VP-Regulatory Sciences Has Expertise In Generic Injectable Business

During nine years at Ben Venue, Gaugh was responsible for strategic planning, financial management, business development, marketing and sales for the company’s $500 million branded generic injectable business, which is now struggling with manufacturing challenges.

Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers

Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel